LY4515100

LY4515100 is an investigational, orally bioavailable small molecule agonist of the gastric inhibitory polypeptide receptor (GIPR), currently under development by Eli Lilly and Company. As a non-peptide incretin mimetic, it is designed to provide a more convenient oral alternative to injectable GIP-based therapies for the treatment of metabolic disorders such as obesity and type 2 diabetes. By selectively activating the GIP receptor, LY4515100 aims to enhance glucose-dependent insulin secretion and potentially influence lipid metabolism and energy expenditure. The drug is currently being evaluated in Phase 1 clinical trials to assess its safety, tolerability, and pharmacokinetic profile in healthy participants.